Abstract: Pediatric uveitis is accounting for  5%~10% of all the uveitis. Most individuals have an insidious onset and persistent duration, ocular complications are common. Most pediatric uveitis are noninfectious and idiopathic, the most common etiologic diagnosis is juvenile idiopathic arthritis. Treatment of pediatric uveitis is tough, the mainstays of therapy include corticosteroids, antimetabolites, and T\|cell inhibitors. In the last decade, biologic agents provide us new methods for treating pediatric uveitis. Intravitreal corticosteroid delivery devices have enhanced our ability to provide longer\|lasting local disease control, but there are very limited data showing the efficacy and safety in children.